Synaptogenix Inc (SNPX)

[runncoach]

There's no telling what's going on. Nobody likes the silence although the share price has been holding with institutional holdings likely increasing. From what company has publicly stated they are likely refining a dosing trial before advancing to phase 3. They are also likely setting the parameters for a FragileX trial. The good thing is we don't currently need any funding to meet those needs, which probably plays into the lack of updates as the drug studies advance. They could be talking to potential partners which would explain the silence but I fully admit it could be wishful thinking, although it is a popular theory I see advanced on small cap bios frequently.

It's not like the company isn't continuing its research and they regularly publish. They just don't toot their own horn all the time. One of the bigger issues here has been putting out incomplete data from the 2B study to live up to their promises to shareholders this past spring. Then we later find out positives from the data and points during the study that were stat sig, and even more positive from patients who did the 17 week check-in. Same for the incredible examples from the 2a study and compassionate use documentation. It is what it is as this point, and that's to say it will take awhile to convince the general market of bryostatin's potential. That doesn't mean that they can't convince potential partners of this data at any time however and honestly that's my hope to move the drug along as quick as possible.

Link to most recently published article.

https://molecularbrain.biomedcentral.com/articles/10.1186/s13041-017-0301-3


Here's a link to